• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

COVID-19 in immunocompromised patients: proposed definition of a new entity with prolonged infection.

作者信息

Gentile Ivan, Schiano Moriello Nicola, Maraolo Alberto Enrico, Rappuoli Rino

机构信息

Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via S. Pansini 5, 80131, Naples, Italy.

Biotecnopolo Foundation, Via Fiorentina 1, 53100, Siena, Italy.

出版信息

New Microbes New Infect. 2025 Aug 21;67:101626. doi: 10.1016/j.nmni.2025.101626. eCollection 2025 Oct.

DOI:10.1016/j.nmni.2025.101626
PMID:40919227
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12409368/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/334c/12409368/37b311878fac/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/334c/12409368/37b311878fac/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/334c/12409368/37b311878fac/gr1.jpg

相似文献

1
COVID-19 in immunocompromised patients: proposed definition of a new entity with prolonged infection.免疫功能低下患者的新冠病毒病：关于一种新的持续性感染实体的拟议定义
New Microbes New Infect. 2025 Aug 21;67:101626. doi: 10.1016/j.nmni.2025.101626. eCollection 2025 Oct.
2
Systemic Inflammatory Response Syndrome全身炎症反应综合征
3
Successful treatment of prolonged COVID-19 with remdesivir and nirmatrelvir/ritonavir in a patient with a history of diffuse large B-cell lymphoma: a case report.在一名有弥漫性大B细胞淋巴瘤病史的患者中，使用瑞德西韦和奈玛特韦/利托那韦成功治疗长期新冠病毒感染：一例报告
J Egypt Natl Canc Inst. 2025 Jun 30;37(1):32. doi: 10.1186/s43046-025-00291-1.
4
Immunocompromised individuals are at increased risk of COVID-19 breakthrough infection, hospitalization, and death in the post-vaccination era: A systematic review.免疫功能低下个体在疫苗接种后时代发生新冠病毒突破性感染、住院和死亡的风险增加：一项系统综述。
Immun Inflamm Dis. 2024 Apr;12(4):e1259. doi: 10.1002/iid3.1259.
5
The Impact of the COVID-19 Pandemic on an Immunocompromised Patient with Allogeneic Haematopoietic Stem Cell Transplant: A Dual Perspective from Patient and Physician Standpoints.2019年冠状病毒病大流行对异基因造血干细胞移植免疫功能低下患者的影响：患者和医生双视角
Oncol Ther. 2025 Aug 25. doi: 10.1007/s40487-025-00364-0.
6
Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients.免疫功能低下患者持续性或复发性严重急性呼吸综合征冠状病毒 2 感染的 2 种抗病毒药物和单克隆抗体三联疗法。
Clin Infect Dis. 2023 Jul 26;77(2):280-286. doi: 10.1093/cid/ciad181.
7
Real-world effectiveness of early anti-SARS therapy in severely immunocompromised COVID-19 outpatients during the SARS-CoV-2 omicron variant era: a propensity score-adjusted retrospective cohort study.SARS-CoV-2奥密克戎变异株时代早期抗SARS治疗对严重免疫功能低下的COVID-19门诊患者的真实世界疗效：一项倾向评分调整的回顾性队列研究
J Antimicrob Chemother. 2024 Dec 2;79(12):3248-3253. doi: 10.1093/jac/dkae351.
8
Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients.系统评价和荟萃分析：替沙格韦单抗/西加韦单抗用于预防免疫功能低下患者 COVID-19 的临床效果。
Br J Haematol. 2023 Jun;201(5):813-823. doi: 10.1111/bjh.18782. Epub 2023 Apr 3.
9
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.新冠病毒疫苗在免疫功能低下人群中的免疫和临床疗效：一项系统评价
Clin Microbiol Infect. 2022 Feb;28(2):163-177. doi: 10.1016/j.cmi.2021.09.036. Epub 2021 Nov 17.
10
Radiologic Abnormalities in Prolonged SARS-CoV-2 Infection: A Systematic Review.长期严重急性呼吸综合征冠状病毒 2 感染的放射学异常：系统评价。
Korean J Radiol. 2024 May;25(5):473-480. doi: 10.3348/kjr.2023.1149.

本文引用的文献

1
Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab.优化免疫功能低下患者的 COVID-19 治疗：瑞德西韦、奈玛特韦/利托那韦和索特罗维单抗的早期联合治疗。
Virol J. 2023 Dec 15;20(1):301. doi: 10.1186/s12985-023-02269-8.
2
Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab-cilgavimab.接受替沙格韦单抗-西加韦单抗预防治疗的患者血清对奥密克戎亚谱系的中和差异
Lancet Infect Dis. 2023 May;23(5):528-530. doi: 10.1016/S1473-3099(23)00208-6. Epub 2023 Apr 5.
3
Immunocompromised Patients with Protracted COVID-19: a Review of "Long Persisters".
患有持续性新冠病毒感染的免疫功能低下患者：“长期感染者”综述
Curr Transplant Rep. 2022;9(4):209-218. doi: 10.1007/s40472-022-00385-y. Epub 2022 Nov 12.
4
SARS-CoV-2 in immunocompromised individuals.免疫功能低下个体中的 SARS-CoV-2。
Immunity. 2022 Oct 11;55(10):1779-1798. doi: 10.1016/j.immuni.2022.09.006. Epub 2022 Sep 13.
5
Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection.瑞德西韦在延长感染患者体内诱导出现 SARS-CoV2 变异株。
Cell Rep Med. 2022 Sep 20;3(9):100735. doi: 10.1016/j.xcrm.2022.100735. Epub 2022 Aug 16.
6
Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant.免疫功能低下的 SARS-CoV-2 奥密克戎变异株感染者在接受 sotrovimab 治疗后出现的耐药性和病毒持续存在情况。
Clin Infect Dis. 2023 Feb 8;76(3):e507-e509. doi: 10.1093/cid/ciac601.